FDA Approves new Schizophrenia Drug Olanzapine (Zyprexa) - More news
INDIANAPOLIS - Eli Lilly & Co. (LLY) received clearance from the Food and Drug Administration to market Zyprexa, or Olanzapine, for the treatment of psychotic disorders. In a press release, the company said the drug offers hope to patients who suffer from schizophrenia or other psychotic disorders.
Zyprexa received marketing clearance in 15 European countries last week. Lilly said that unlike older antipsychotic medications, Zyprexa has a low incidence of extrapyramidal syndrome events, such as abnormal muscle spasms, Parkinson's disease-like symptoms, abnormal jerking or writhing, and an inability to sit still. The drug also showed no incidence agranulocytosis, a sometimes fatal blood disorder associated with other psychotropic compounds.
However, the drug did have some side effects during clinical trials,
such as dizziness, sleepiness, weight gain, light headedness, constipation,
and personality disorder. Zyprexa is expected to be available to consumers
within the next 48 hours.
[ Home] [News]